BioWorld

Sep. 29, 2006

FDA Clears Amgen's Vectibix, Adds To ImClone's Troubles

Late Wednesday, the FDA approved the next in a growing line of targeted cancer therapies, Amgen Inc.'s Vectibix (panitumumab). (BioWorld Today) Read More

Athenagen Series B Garners $50M For Alzheimer's, AMD

Grant Gives Alnylam $23M For Anti-Ebola Virus Work

Startup Alvine Aims At Celiac Disease, Closes $21M Round

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

GT-02897 exerts efficacy in preclinical multiple myeloma

BioWorld Science

Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...